CD4 and Alzheimer disease: We found that higher levels of CD4, CD20, IL-21, IgG1, and IgG3 and lower levels of IgA in MPR tumor lesions of AD and SCC patients after neoadjuvant chemoimmunotherapy, although statistical significance was not reached in AD due to the small number of cases, suggesting that similar antitumor immune responses occur in the local tumor microenvironment of AD and SCC patients during neoadjuvant chemoimmunotherapy (Supplementary Table S4).